Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack patients may get safer blood thinners tailored to their genes

NCT ID NCT03729401

Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether personalizing blood-thinning drugs based on a patient's genetics and risk factors could reduce bleeding after a heart attack. It enrolled 39 patients who had already been on standard dual therapy for a year. The trial was terminated early, so the findings are not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aspirin, Ticagrelor, Clopidogrel
What this could lead to
If successful, this could help doctors choose the safest blood-thinning drug for each patient after a heart attack, reducing bleeding side effects.
What could go wrong
The study was terminated early with very few participants (39 of 260 planned), so results are too limited to draw reliable conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

39 people

The number who actually took part.

Started

Aug 2019

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \>50 years old at 1-year after myocardial infarction (non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI)) during which they had percutaneous coronary intervention (PCI) * Compliant with dual antiplatelet therapy (DAPT) for ≥ 1 year without an ischemic or bleeding complication after PCI * Still on DAPT regimen at enrollment * Patients must have 1 of the following atherothrombotic risk enrichment criteria: i) Age≥ 65 years ii) Diabetes iii) 2nd Prior MI (\>1 year ago) iv) multi-vessel coronary disease v) creatinine clearance (CrCl) \<60 mL/min. Exclusion Criteria: * Intolerance to ticagrelor or clopidogrel * \>18 months post percutaneous coronary intervention (PCI) and myocardial infarction (MI) * Requirement of a P2Y12 inhibitor * Requirement of oral anticoagulation * Take concurrent CYP3A inducing drugs which may interact with ticagrelor (e.g. anti-epileptic drugs) * History of stroke, TIA or intracranial bleed * Recent GI bleed or major surgery * Life expectancy of \< 1 year * Platelet count \< 100,000/μl * Bleeding diathesis * On dialysis * Severe liver disease * At risk for bradycardia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Myocardial infarction

Contacts and locations

Locations

  • University of Ottawa Heart Institute

    Ottawa, Ontario, K1Y4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.